Thank you for registering your account
Thanks for joining touchRESPIRATORY to hear about news and updates from across the Respiratory community.
We’ve sent you an email to verify your email address. Please click on the link to confirm your account.
You can review your email preferences at any time or update your account details
Investigating KRASG12C inhibitors: How might they improve outcomes for patients with solid tumours?
Prof. Tony Mok discusses the role of KRAS mutations in solid tumours and the impact of KRASG12C inhibitors on patient outcomes.
- Describe the role of KRAS in tumourigenesis and the implications of the KRASG12C mutation for patients with solid tumours
- Evaluate the efficacy and safety of KRASG12C inhibitors in advanced and metastatic KRAS-mutated solid tumours
- Formulate strategies to overcome intrinsic or acquired resistance to KRASG12C-directed therapies
Biomarker-guided management of NSCLC: Current and future strategies
Select a discussion in the hub to watch our multidisciplinary faculty share their insights on biomarker testing methods and interpretation of results to guide treatment selection for a patient with advanced NSCLC.
- Discuss current recommendations for biomarker testing in patients with advanced NSCLC
- Identify the most appropriate biomarker testing methods for each patient with advanced NSCLC
- Use biomarker testing results to select appropriate targeted and immuno-oncological treatment options for patients with advanced NSCLC
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]
Charlie Strange, CHEST 2022: A predictive model to diagnose alpha-1 antitrypsin deficiency
Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that remains highly undiagnosed. It is estimated that between 1 to 5% of patients with chronic obstructive pulmonary disease (COPD) have AATD; however is often not diagnosed. We caught up with Prof. Charlie Strange (MUSC, Charleston, SC, USA) to discuss what methods are currently available for the […]
Véronique Suttels, World Conference on Lung Health 2022: Point-of-care ultrasound as a potential triage tool for tuberculosis (Part 1)
Pulmonary tuberculosis (TB) is a contagious infectious disease caused by Mycobacterium tuberculosis, symptoms can include a cough, chest pain and breathlessness, and in some cases the infection can spread to other organs. In this touchRESPIRATORY interview, we speak with Dr. Veronique Suttels (Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland) to discuss the strengths and limitations of […]
Francesca Conradie, World Conference on Lung Health 2022: A delamanid-bedaquiline regimen for rifampicin-resistant tuberculosis- findings from BEAT tuberculosis
BEAT tuberculosis (NCT04062201) investigated treatment with a short course of a delamanid-bedaquiline regimen for rifampicin resistant tuberculosis (RR-TB) in South Africa. It was a pleasure to talk with Dr Francesca Conradie (University of the Witwatersrand, Johannesburg, South Africa) around the aims and design of the BEAT tuberculosis study and the findings from the interim analysis. […]
Tackling ‘People Remodelling’ in Corticosteroid-dependent Asthma with Type-2 Targeting Biologics and a Formal Corticosteroid Weaning Protocol
touchREVIEWS in Respiratory & Pulmonary Diseases. 2022;7(2):44–7 DOI: https://doi.org/10.17925/USRPD.2022.7.2.44
Asthma is a common and heterogeneous disease affecting approximately 10% of the population.1 Severe asthma – a subset of the disease that affects a fraction of patients with asthma but comprises more than half of the morbidity, mortality and costs relating to asthma – is predominantly caused by smouldering type-2 eosinophilic airway inflammation.2,3 Until now, the main strategy […]
Innovations in Bronchoscopy: Robotic-assisted Bronchoscopy
touchREVIEWS in Respiratory & Pulmonary Diseases. 2022;7(2):41–3 DOI: https://doi.org/10.17925/USRPD.2022.7.2.41
Lung cancer remains the leading cause of cancer-related death.1 However, five-year survival in lung cancer varies greatly based on the stage of the disease at diagnosis.2 Early lung cancer diagnosis through screening with low-dose computed tomography (CT) demonstrated a 20% reduction in lung cancer mortality in current or former smokers with a history of 30 or more […]
Brensocatib: An Anti-neutrophil Elastase Drug With Potential in the Management of Bronchiectasis
touchREVIEWS in Respiratory & Pulmonary Diseases. 2022;7(2):34–5 DOI: https://doi.org/10.17925/USRPD.2022.7.2.34
Judith Durham (of The Seekers fame) died in August this year from bronchiectasis – a timely reminder of the morbidity and mortality associated with this disease of chronic airway inflammation and damage and a tribute to Durham’s personal and professional resilience.1 The measles that initiated Durham’s airway damage is mercifully now rare (although bronchiectasis can develop […]
Dexpramipexole: A Potential Non-biologic Alternative for Patients with Eosinophilic Asthma?
touchREVIEWS in Respiratory & Pulmonary Diseases. 2022;7(2):36–7 DOI: https://doi.org/10.17925/USRPD.2022.7.2.36
There is a wide range of eosinophil-associated disorders, from common conditions, such as eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), to rarer ones, such as eosinophilic gastrointestinal disorders and hypereosinophilic syndrome (HES). The advent of eosinophil-targeted therapies is uncovering which of these disorders are primarily treatable by reducing blood or tissue eosinophils, thus […]